<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373632</url>
  </required_header>
  <id_info>
    <org_study_id>20110611</org_study_id>
    <nct_id>NCT01373632</nct_id>
  </id_info>
  <brief_title>Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease</brief_title>
  <acronym>FESTA</acronym>
  <official_title>Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sirolimus-eluting stent (SES) has been world-widely used in clinical practice in treating
      patients with coronary artery disease (CAD). The efficacy and safety of Excel SES (JW
      Medical, Shandong, China, MA) with biodegradable polymer has been proved by several clinical
      trials. Here the investigators design a prospective, multicenter, randomized clinical study
      in purpose of identifying the non-inferiority in the efficacy and safety in treating CAD
      patients by Firebird 2 SES (Microport, Shanghai) with durable polymer, comparing with Excel
      SES.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-stent late lumen loss at 9 months' angiographic follow-up</measure>
    <time_frame>9 months</time_frame>
    <description>patients are planned to receive angiographic follow-up at 9 months after index procedure, and in-stent late lumen loss will be analyzed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>target vessel failure</measure>
    <time_frame>2 years after index procedure</time_frame>
    <description>defined as the occurrence of any of the following within 1 and 2 years after the index procedure: death from cardiac causes, Q-wave or non-Q-wave myocardial infarction, or revascularizationof the target vessel (emergency or elective coronaryartery bypass grafting [CABG] or repeated percutaneous transluminal coronary angioplasty [PTCA]).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">570</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Firebird 2 stent group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients who receive Firebird 2 stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Excel stent group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients who receive Excel stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Firebird 2 sirolimus-eluting stent</intervention_name>
    <description>the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform</description>
    <arm_group_label>Firebird 2 stent group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excel sirolimus-eluting stent</intervention_name>
    <description>the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform</description>
    <arm_group_label>Excel stent group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  male or un-pregnant female

          -  stenosis &gt; 70% in one of major the epicardial coronary arteries

          -  no contra-indications of stent implantation

          -  singed the informed consent

        Exclusion Criteria:

          -  acute myocardial infarction within one week

          -  have contra-indications of stent implantation or can not tolerate dual antiplatelet
             therapy

          -  no history of stent implantation within last one-year

          -  received other brand coronary stent during index procedure

          -  with no achievement of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WeiFeng Shen, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665215</phone_ext>
      <email>rjshenweifeng@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xian Zhang, MD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665215</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>WeiFeng Shen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Zhang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang Q, Xu B, Yang YJ, Zhang RY, Li JP, Qiao SB, Zhang JS, Hu J, Qin XW, Hong T, Chen JL, Huo Y, Shen WF, Gao RL. Sirolimus-eluting cobalt alloyed stents in treating patients with coronary artery disease: six-month angiographic and one-year clinical follow-up result. A prospective, historically controlled, multi-center clinical study. Chin Med J (Engl). 2007 Apr 5;120(7):533-8.</citation>
    <PMID>17442198</PMID>
  </reference>
  <reference>
    <citation>Han Y, Jing Q, Chen X, Wang S, Ma Y, Liu H, Luan B, Wang G, Li Y, Wang Z, Wang D, Xu B, Gao R. Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv. 2008 Aug 1;72(2):177-83. doi: 10.1002/ccd.21600.</citation>
    <PMID>18655114</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name_title>
    <organization>Cardiovascular Department</organization>
  </responsible_party>
  <keyword>significant stenosis (&gt;70% of lumen stenosis)</keyword>
  <keyword>epicardial coronary arteries</keyword>
  <keyword>clinical ischemic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

